Preview Mode Links will not work in preview mode

Aug 14, 2023

Featuring perspectives from Dr Neeraj Agarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Susan F Slovin, including the following topics:

  • Introduction: Current landscape of prostate cancer treatment (0:00)
  • Relevance of homologous recombination repair mutations in castration-resistant prostate cancer: Treatment with PARP inhibitors as monotherapy — Dr Antonarakis (12:33)
  • Phase III PROpel and MAGNITUDE trials — Dr Slovin (35:44)
  • PARP inhibitor combination treatments for advanced prostate cancer — Dr Agarwal (57:08)
  • Future directions in the use of PARP inhibitors for prostate cancer — Prof Fizazi (1:23:49)
  • Journal Club (1:35:53)
  • Case discussions (2:11:57)

CME information and select publications